| EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S Gabriel, P Herman, ... Science 304 (5676), 1497-1500, 2004 | 12121 | 2004 |
| MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 5521 | 2007 |
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists … NI Lindeman, PT Cagle, MB Beasley, DA Chitale, S Dacic, G Giaccone, ... Journal of Thoracic Oncology 8 (7), 823-859, 2013 | 1986 | 2013 |
| Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology … MM Li, M Datto, EJ Duncavage, S Kulkarni, NI Lindeman, S Roy, ... The Journal of molecular diagnostics 19 (1), 4-23, 2017 | 1744 | 2017 |
| Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American … NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Archives of pathology & laboratory medicine 142 (3), 321-346, 2018 | 1601 | 2018 |
| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1420 | 2017 |
| Characterizing the cancer genome in lung adenocarcinoma BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, ... Nature 450 (7171), 893-898, 2007 | 1296 | 2007 |
| EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ... Clinical cancer research 14 (13), 4275-4283, 2008 | 1259 | 2008 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 1250 | 2010 |
| LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807-810, 2007 | 1200 | 2007 |
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ... Blood, The Journal of the American Society of Hematology 125 (9), 1367-1376, 2015 | 1054 | 2015 |
| Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review JD Merker, GR Oxnard, C Compton, M Diehn, P Hurley, AJ Lazar, ... Archives of pathology & laboratory medicine 142 (10), 1242-1253, 2018 | 1015 | 2018 |
| Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ... Clinical cancer research 15 (16), 5216-5223, 2009 | 858 | 2009 |
| A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011 | 725 | 2011 |
| Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or erlotinib DM Jackman, BY Yeap, LV Sequist, N Lindeman, AJ Holmes, VA Joshi, ... Clinical Cancer Research 12 (13), 3908-3914, 2006 | 711 | 2006 |
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine EM Van Allen, N Wagle, P Stojanov, DL Perrin, K Cibulskis, S Marlow, ... Nature medicine 20 (6), 682-688, 2014 | 575 | 2014 |
| A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry M Mino-Kenudson, LR Chirieac, K Law, JL Hornick, N Lindeman, EJ Mark, ... Clinical Cancer Research 16 (5), 1561-1571, 2010 | 556 | 2010 |
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013 | 456 | 2013 |
| Pathomic fusion: an integrated framework for fusing histopathology and genomic features for cancer diagnosis and prognosis RJ Chen, MY Lu, J Wang, DFK Williamson, SJ Rodig, NI Lindeman, ... IEEE Transactions on Medical Imaging 41 (4), 757-770, 2020 | 441 | 2020 |
| Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, ... The lancet oncology 20 (7), 1011-1022, 2019 | 440 | 2019 |
Pasi JanneDana Farber Cancer InstituteПодтвержден адрес электронной почты в домене dfci.harvard.edu
